Barclays Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective boosted by research analysts at Barclays from $60.00 to $62.00 in a research note issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 27.10% from the stock’s previous close.

Several other equities research analysts have also issued reports on the stock. Oppenheimer increased their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. The Goldman Sachs Group increased their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $56.00.

Tarsus Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ:TARS opened at $48.78 on Monday. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.14. The stock has a 50-day simple moving average of $51.04 and a 200-day simple moving average of $39.10. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market capitalization of $1.86 billion, a P/E ratio of -12.80 and a beta of 1.02.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in TARS. R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at about $53,000. Baader Bank Aktiengesellschaft acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $249,000. FMR LLC increased its holdings in Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares during the last quarter. SG Americas Securities LLC increased its holdings in Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after purchasing an additional 3,379 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Tarsus Pharmaceuticals by 64.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after purchasing an additional 2,879 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.